This page is updated frequently with new Endothelial-related patent applications.
|Multifunctional nitroxide derivatives and uses thereof|
Multifunctional nitroxide derivatives contain a potassium channel opener and a reactive oxygen species (ros) degradation catalyst that can act as an anti-oxidant. Pharmaceutical compositions can include the derivatives.
Radikal Therapeutics Inc
|Synthetic antibody mimic peptides|
The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (pdcs) comprising the mimic peptides disclosed herein.
|Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy|
Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies.
Batu Biologics, Inc.
|Method of therapy and diagnosis of endothelial dysfunction|
The invention discloses a method of therapy of endothelial dysfunction, by administering microrna let-7g to a subject in need, wherein the microrna let-7g inhibits smad2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.. .
Kaohsiung Medical University
|Inhibition of tumor angiogenesis by checkpoint inhibitors and active vaccination|
Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors.
Batu Biologics, Inc.
|Controllable formation of microvascular networks using sacrificial microfiber templates|
The present disclosure relates to fabricating sacrificial microfiber templates from any biocompatible and resorbable materials depending on the time needed for dissolving the microfiber template to free the endothelial tube with open lumen. Microfiber networks with distinct patterns and defined diameters initially serve as a template to support the growth of vascular cells (endothelial cells or their progenitor cells, or combined with mural cells such as pericytes) and then dissolve to form an empty endothelium lumen.
The Trustees Of The Stevens Institute Of Technology
|Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide|
This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject.
The Regents Of The University Of Colorado, A Body Corporate
|Methods and stenting comprising enhanced embolic protection coupled with improved protections against restenosis and thrombus formation|
Apparatus and methods for stenting are provided comprising a stent attached to a porous biocompatible material that is permeable to endothelial cell ingrowth, but impermeable to release of emboli of predetermined size. Preferred stent designs are provided, as well as preferred manufacturing techniques.
Abbott Laboratories Vascular Enterprises Limited
|Methods and formulations for treating vascular eye diseases|
The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (ang-2) inhibitor such as an anti-ang-2 antibody in combination with a vascular endothelial growth factor (vegf) antagonist (e.g., aflibercept)..
Regeneron Pharmaceuticals, Inc.
|Regeneration of a functional pulmonary vascular bed|
A method for vascular regeneration comprises delivering endothelial cells to a lung scaffold, delivering perivascular cells to the lung scaffold, and providing a multiphase culture program to the scaffold. The multiphase culture program comprises a first phase including delivering an angiogenic medium, e.g., having 40-100 ng/ml of pro-angiogenic factors, and a second phase including delivering a stabilization medium, e.g., having 0.5-2% of serum and 1-20 ng/ml of angiogenic factors..
The General Hospital Corporation
Vegf antagonist formulations
Formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of seq id no:4..
Regeneron Pharmaceuticals, Inc.
Multivalent ligands targeting vegfr
Compounds that target vascular endothelial growth factor receptors for therapy and imaging are disclosed. Methods for making the compounds and detecting or imaging cells expressing vegfr using the compounds are also provided.
The Methodist Hospital System
endothelial cells can become susceptible to disease when subjected to disturbed (atheroprone) blood flow patterns, which naturally occur in known locations in human arteries. Atheroprone flow is non-laminar, with low fluid shear stress magnitude and an oscillatory pattern representative in the temporal signature.
Massachusetts Institute Of Technology
Surface modification method and structure for improving hemocompatibility of biomedical metallic substrates
The present invention relates to a surface modification method for improving the hemocompatibility of biomedical metallic substrate, comprising: fixing a sulfur-containing monomolecular film on the surface of oxide layer of a biomedical metallic substrate by molecular self-assembly. The surface modification will improve the hydrophilicity and hemocompatibility of the biomedical metallic substrate in contact with the blood, and ensure that the biomedical metallic substrate is non-toxic to the endothelial cells..
National Chung-hsing University
Implantable medical device having enhanced endothelial migration features and methods of making the same
An implantable medical device having enhanced endothelial migration features, generally comprises: a structural member including a leading edge and a trailing edge interconnected by a third surface region, the leading edge including a second surface region in a generally curvilinear cross-section, and the trailing edge including a fourth surface region in a generally curvilinear cross-section, whereby blood flow over the second surface region generate shear stress at the second surface region without an eddy region in the second surface region.. .
Vactronix Scientific, Inc.
Hyaluronic acid modified by sphingosine-1-phosphoric acid
Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia/reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and/or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia/reperfusion.. .
University Of Tsukuba
Individualized treatment of eye disease
Methods are described for individualizing a patient's treatment for an eye disease that is mediated by vascular-derived endothelial growth factor.. .
Mayo Foundation For Medical Education And Research
Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions
Methods and compounds for research and treatment of portal hypertension. The use of racemic or non-racemic mixtures of furopyridine isomers to stimulate enos function in sinusoidal endothelial cells and to increase no production in both normal sinusoidal endothelial cells and injured endothelial cells..
Targeted treatment of anerobic cancer
The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (vegf) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor.
University Hospitals Cleveland Medical Center
Implantable biomaterials having engineered functional surfaces
Implantable materials having defined patterns of affinity regions for binding endothelial cells and providing for directed endothelial cell migration across the surface of the material. The affinity regions include photochemically altered regions of a material surface and physical members patterned on the material surface that exhibit a greater affinity for endothelial cell binding and migration than the remaining regions of the material surface..
Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc.
Peptide having anti-inflammatory, osteogenic and hair growth promoting activities, and use of same
Provided is a peptide, which has an anti-inflammatory activity and an activity for promoting osteogenic differentiation, formed from the amino acid sequence selected from the group comprising the amino acid sequences of seq id no: 1, seq id no: 2, and seq id no: 3. And provided is a peptide, which has a hair growth promoting activity, formed from the amino acid sequence selected from the group comprising the amino acid sequences of seq id no: 1 and seq id no: 2.
Caregen Co., Ltd.
Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.. .
Purdue Research Foundation
Agent for preventing or ameliorating vascular endothelial malfunction
An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved no production enhancing effect is provided. A no production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
Kyowa Hakko Bio Co., Ltd.
Assessing endothelial function and providing calibrated ufmd data using a blood pressure cuff
Methods and apparatus are provided for assessing endothelial function in a mammal. In certain embodiments the methods involve using a cuff to apply pressure to an artery in a subject to determine a plurality of baseline values for a parameter related to endothelial function as a function of applied pressure (pm); b) applying a stimulus to the subject; and applying external pressure pm to the artery to determine a plurality of stimulus-effected values for the parameter related to endothelial function as a function of applied pressure (pm); where the baseline values are determined from measurements made when said mammal is not substantially effected by said stimulus and differences in said baseline values and said stimulus-effected values provide a measure of endothelial function in said mammal..
The Regents Of The University Of California
Method to screen out false positives in a circulating tumor cell assay
Provided herein are methods of screening a patient sample in a circulating tumor cell assay for false positives as well as methods of performing a circulating tumor cell detection assay. Also provided herein are methods of simultaneously identifying, and methods of distinguishing between, a circulating tumor cell and a circulating endothelial cell in a patient sample.
Siemens Healthcare Diagnostics Inc.
Enrichment and characterization of human corneal endothelial cells (hcenc) with novel monoclonal antibody
This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hcencs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed peroxiredoxin-6 (prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal en dothelial cells from a mixture of cell.. .
Singapore Health Services Pte Ltd
Bone repair compositions
A composition including, (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid, is provided. Moreover, a kit which includes: a syringe, a mineral particle covered with endothelial cells and mesenchymal cells organized in 2 or more cell layers attached to the mineral particle, and hyaluronic acid, is also provided.
Bonus Therapeutics Ltd.
Dietary compositions for reducing blood glucose levels and for weight management
The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.
Compositions and methods of inhibiting histone deacetylases
The present invention provides compositions and methods for treating pulmonary hypertension. In one aspect, a method is included for increasing myocyte enhancer factor 2 (mef2) activity in an endothelial cell comprising exposing the cell to a class iia histone deacetylase inhibitor.
Silk-based scaffold platform for engineering tissue constructs
The inventions provided herein relate to silk-based scaffolds and methods of producing the same, which can be used for a range of tissue engineering applications. The fabrication methods described herein provide a versatile platform to incorporate hollow conduits (e.g., for nutrient/oxygen delivery) through three-dimensional silk-based scaffolds that have tunable bulk properties (e.g., but not limited to, porosity, mechanical, degradation rate) and allow endothelialization and/or cell compartmentalization, for engineering a variety of complex tissue equivalents..
Method for generating endothelial colony forming cell-like cells
The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent cells into endothelial colony forming cell-like cells (ecfc-like cells) is provided.
Indiana University Research And Technology Corporation
Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
The blood-brain barrier (bbb) prevents transport of molecules larger than 500 dal tons from blood to brain. Receptor-mediated transcytosis (rmt) facilitates transport across the bbb of specific molecules that bind receptors on brain endothelial cells that form the bbb.
National Research Council Of Canada